Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Declines By 39.6%

BioCardia, Inc. (NASDAQ:BCDA) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 50,400 shares, a decline of 39.6% from the December 15th total of 83,400 shares. Based on an average trading volume of 48,500 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.3% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research note on Wednesday, December 18th.

BioCardia Stock Performance

BCDA stock traded down $0.03 during mid-day trading on Thursday, reaching $2.18. 18,532 shares of the stock traded hands, compared to its average volume of 37,543. BioCardia has a one year low of $1.63 and a one year high of $9.42. The stock has a market capitalization of $9.97 million, a PE ratio of -0.52 and a beta of 1.26. The business has a 50-day moving average price of $2.19 and a two-hundred day moving average price of $2.58.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.